Pioglitazone to Reduce Restenosis After Bare-Metal Stent Placement?⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.  by Nissen, Steven E.
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ioglitazone to Reduce
estenosis After Bare-Metal
tent Placement?*
teven E. Nissen, MD
leveland, Ohio
n this issue of JACC: Cardiovascular Interventions, Takagi
t al. (1) report the results of a small, multicenter, random-
zed trial suggesting that pioglitazone might reduce the risk
f restenosis in diabetic patients who receive a bare-metal
tent. The study design was simple and elegant. The authors
andomized a typical population of type II diabetes patients
ith stable or unstable angina to pioglitazone versus other
ral hypoglycemic agents after bare-metal stent placement
or a single culprit lesion. The results are consistent with a
avorable effect of pioglitazone on neointimal proliferation
nd clinical restenosis, although the statistical significance
f these findings was marginal. Target lesion revasculariza-
ion, the most clinically relevant measure of restenosis, was
educed from 29.8% to 12.5%, p  0.04. The neointimal
ndex (the percent of the stent volume occupied by neoin-
ima), the most clinically relevant intravascular ultrasound
IVUS) measure of neointimal proliferation, was reduced
rom 40.5% to 31.1%, p  0.01.
See page 524
Several aspects of this study are notable. The success of
he study reminds us that, in an era of $100 million
mega-trials”, important scientific observations can be ac-
omplished by dedicated investigators performing a metic-
lous, small randomized trial with a limited budget. The
uthors succeeded in this endeavor by applying many of the
est practices of large randomized trials in conducting their
mall study. They enrolled a fairly homogeneous patient
opulation, thereby avoiding the confounding effects of
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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either income nor a tax deduction.atient variability. The investigators used a core laboratory
o perform IVUS and angiographic measurements to avoid
he variability inherent in “locally” measured images. They
anaged the randomization process well, with no clinically
elevant differences observed in baseline characteristics be-
ween the 2 study groups (Table 1 in Takagi et al. [1]). They
nrolled patients undergoing intervention on a single dis-
rete coronary lesion, avoiding the confounding effects of
reatment of multiple lesions. Commendably, the investiga-
ors prospectively performed formal power calculations to
etermine the optimal sample size.
There were a few aspects of the study conduct that were
uboptimal. To keep the sample size low, the study was
owered at 80% (not the more typical 90%), and the authors
sed very aggressive assumptions in their power calculations,
ostulating a reduction in restenosis rate from 43% to 17%
or the pioglitazone treatment group. They actually ob-
erved a 17% restenosis rate in the pioglitazone group but a
etter-than-expected 35% restenosis rate in the control
roup, resulting in a p value that fell just short of conven-
ional levels of statistical significance, p  0.06. Repeat
VUS measurements were obtained in only 56 of 97 patients
58%). As a consequence, 1 measure of proliferation, abso-
ute in-stent neointimal volume, was substantially smaller in
he pioglitazone group (48.0 mm3 vs. 62.7 mm3), but again,
he statistical significance was marginal, p 0.07. Thus, the
mall study size resulted in findings that were not statisti-
ally robust, particularly without a statistical correction for
he multiplicity of end points. This potential for type I error
mposes limitations on interpretation. Therefore, the find-
ngs must be considered hypothesis-generating rather than
ypothesis-proving.
Despite these limitations, the potential importance of the
urrent findings should not be underestimated. In the 4
ecades since the first coronary angioplasty, the quest to
evelop a systemic therapy to reduce restenosis has been
raught by frustration and failure (2). Nearly all pharmaco-
ogical efforts to limit restenosis were abandoned after the
uccessful development of drug-eluting stents (DES). Per-
aps, termination of such efforts was premature. Recently,
he emergence of concerns about potentially catastrophic
ate stent thrombosis and the need for 12 months of dual
ntiplatelet therapy have exposed some critical weaknesses
n the DES approach. Clearly, for some patients, DES is
ot an option, including patients awaiting urgent planned
ajor surgery or those who face increased bleeding hazards.
e must view any systemic therapy that shows a favorable
ffect on restenosis as a welcome addition to the therapeutic
rmamentarian. Furthermore, it must be emphasized that
estenosis still occurs in10% of patients who receive DES,
articularly in patients with diabetes (3). Although the
uthors did not study patients receiving DES, the potential
f this approach to further reduce restenosis, if confirmed,
ould be a valuable addition to current therapy.
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533This study also provides interesting insights into the
iological effects of a controversial group of drugs, the
hiazolidinedione (TZD) class. Introduced with great fan-
are in the late 1990s, the TZDs are peroxisome proliferator-
ctivated receptor (PPAR)-gamma agonists. The PPAR-
amma agonists modulate the activity of a wide array of genes
ffecting a large number of biological processes (4). At the time
f introduction, TZDs seemed to have many desirable prop-
rties for treatment of diabetes mellitus, including a robust and
urable reduction in glycosylated hemoglobin, potent anti-
nflammatory properties, and antithrombotic effects. Then
ame disquieting findings; these drugs could cause fluid reten-
ion and precipitate congestive heart failure in susceptible
ndividuals (5). A closely related drug, muraglitazar, was not
pproved by the Food and Drug Administration after we
ublished a pooled analysis of Phase II and III data showing a
ignificant increase in ischemic cardiovascular events (6). In
007, we published a meta-analysis of the most widely used
ZD, rosiglitazone, that showed a significant increase in the
ncidence of myocardial infarction and possibly cardiovascular
eath (7). These revelations have created an atmosphere of
oncern and suspicion about the entire class.
In the setting of a drug class currently undergoing
econsideration, how do we explain the current favorable
ndings? It is important to understand that TZDs are
nlike most typical drug “classes.” Each TZD is a unique
PAR agonist that upregulates and downregulates some-
hat different genes (8). Accordingly, the biological effects
f the TZDs differ considerably. For example, rosiglitazone
ncreases low-density lipoprotein cholesterol (LDL-C) and
hows minimal effects on triglycerides, whereas pioglitazone
as minimal effects on LDL-C and lowers triglycerides (9).
e recently published, as noted by the authors, an IVUS
egression–progression trial that showed slowing of disease
rogression in diabetic patients treated with pioglitazone,
ompared with glimepiride (10). A large clinical outcomes
rial showed a strong trend toward reduction in major
dverse cardiovascular events with pioglitazone treatment
11). A meta-analysis of Phase II, III, and IV trials of
ioglitazone also showed a favorable effect on cardiovascular
utcomes (12). Accordingly, despite concerns about other
rugs in the “class,” the hypothesis that pioglitazone might
educe restenosis is biologically plausible.
Regardless of mechanism of benefit, the results of this
tudy are notable. Systemic therapy to prevent restenosis is
ot a futile endeavor. The current results must be replicated
n a larger trial with greater statistical power, and the rypothesis should be explored in separate study of patients
eceiving DES. Nonetheless, the current study represents a
ood start.
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